| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1468-1331.2006.01359.X |
| P698 | PubMed publication ID | 16796590 |
| P50 | author | Terence J O'Brien | Q39425688 |
| P2093 | author name string | J Graham | |
| M J Eadie | |||
| C Solinas | |||
| C M Lander | |||
| F J E Vajda | |||
| A Hitchcock | |||
| P2860 | cites work | Lamotrigine plasma levels reduced by oral contraceptives | Q43774655 |
| Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study | Q43986196 | ||
| Lamotrigine clearance during pregnancy | Q44075693 | ||
| Preliminary results on pregnancy outcomes in women using lamotrigine | Q44169564 | ||
| Major malformations in offspring of women with epilepsy | Q44324825 | ||
| Epilepsy and pregnancy: lamotrigine as main drug used | Q44678739 | ||
| The impact of pregnancy and childbirth on the metabolism of lamotrigine. | Q44743465 | ||
| Maternal valproate dosage and foetal malformations | Q46648132 | ||
| Malformations in Offspring of Women with Epilepsy: A Prospective Study | Q59222991 | ||
| Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group | Q28245647 | ||
| Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy | Q28291026 | ||
| Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate | Q28371105 | ||
| Newer anticonvulsants: comparative review of drug interactions and adverse effects. | Q33993665 | ||
| Anti-epileptic drugs in pregnancy: current safety and other issues | Q35095179 | ||
| Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation | Q35147180 | ||
| Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs | Q35172260 | ||
| Management issues for women with epilepsy: neural tube defects and folic acid supplementation | Q35540886 | ||
| Minor anomalies in offspring of epileptic mothers | Q39296948 | ||
| Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. | Q40478338 | ||
| Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality | Q43650811 | ||
| P433 | issue | 6 | |
| P921 | main subject | seizure | Q6279182 |
| P304 | page(s) | 645-654 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry | |
| P478 | volume | 13 |
| Q60667230 | Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children |
| Q36998327 | Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries |
| Q37301548 | Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes? |
| Q37301555 | Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics |
| Q37341158 | Antiepileptic drug use in women of childbearing age. |
| Q55716842 | Antiepileptic drugs and pregnancy outcomes. |
| Q34526112 | Antiepileptic drugs during pregnancy in primary care: a UK population based study |
| Q34905287 | Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? |
| Q33949402 | Antiepileptic drugs in women with epilepsy during pregnancy |
| Q37685323 | Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine |
| Q33861432 | Comparative safety of anti-epileptic drugs among infants and children exposed in utero or during breastfeeding: protocol for a systematic review and network meta-analysis |
| Q28546202 | Congenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort Study |
| Q36658100 | Does increased levetiracetam clearance during pregnancy require planned intervention? |
| Q88564502 | Dose-Dependent Teratology in Humans: Clinical Implications for Prevention |
| Q26991704 | Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks |
| Q37029076 | Effects of in utero antiepileptic drug exposure |
| Q37044837 | Ethical and regulatory issues related to pregnancy registries and their outcomes |
| Q46070797 | Influences on seizure activity in pregnant women with epilepsy |
| Q36660112 | Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency |
| Q38010785 | Lamotrigine use in pregnancy |
| Q34722379 | Management of epilepsy during pregnancy |
| Q38655275 | Management of women with epilepsy: from preconception to post-partum |
| Q48581399 | Patient knowledge about issues related to pregnancy in epilepsy: a cross-sectional study |
| Q36329558 | Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcom |
| Q24198152 | Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome |
| Q24242734 | Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome |
| Q37138858 | Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts |
| Q37203417 | Pregnancy registries: what do they mean to clinical practice? |
| Q35236942 | Pregnancy, epilepsy, and anticonvulsants. |
| Q34340977 | Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism |
| Q38516298 | Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis |
| Q38577939 | Safety of anticonvulsant agents in pregnancy. |
| Q43737555 | Teratogenesis in repeated pregnancies in antiepileptic drug-treated women |
| Q34267151 | Teratogenic effects of antiepileptic drugs |
| Q37902128 | Teratogenic exposures |
| Q37334220 | Teratogenicity and hyperprolactinemia |
| Q35942004 | Teratogenicity of lamotrigine |
| Q37786743 | The Australian Pregnancy Register of Anti-epileptic Drugs : 10 years of progress |
| Q46908652 | The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies |
| Q33394803 | The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: what's the evidence? |
| Q36603158 | Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? |
| Q46209070 | Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy |
| Q43054183 | Valproate for treatment of women with epilepsy: recommendations of the German Society for Epileptology |
| Q36752925 | Women and epilepsy: review and practical recommendations |
| Q30245064 | Women with epilepsy: clinically relevant issues |
Search more.